What’s the current market cap for Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals (XENE) has a market cap of $5bn as of June 17, 2026.

What is the P/E ratio for Xenon Pharmaceuticals stock?

The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of June 17, 2026.

Does Xenon Pharmaceuticals stock pay dividends?

No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Xenon Pharmaceuticals dividend payment date?

Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.

What is the beta indicator for Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Xenon Pharmaceuticals stock | $XENE Share Price

13:30

15:10

16:45

18:25

20:00

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Ticker

$XENE

Sector

Health

Primary listing

NASDAQ

Employees

364

Headquarters

Burnaby, Canada

Website

www.xenon-pharma.com

XENE Metrics

BasicAdvanced

$5bn

-$4.71

0.65

What the Analysts think about XENE

Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.

Bulls say / Bears say

The Phase 3 X-TOLE2 study of XEN1101 (azetukalner) demonstrated a median 53.2% reduction in focal onset seizure frequency versus 10.4% for placebo, meeting primary and key secondary endpoints and supporting a differentiated clinical profile (Reuters).

Following its Q1 2026 earnings, Xenon reported a cash runway into 2029, ensuring funding for late-stage trials, the planned NDA submission, and commercial preparations (Nasdaq).

Analyst consensus is overwhelmingly positive, with 11 analysts rating XENE as a “Strong Buy” and an average price target of $72.18 implying roughly 33% upside over the next year (StockAnalysis).

Xenon remains pre-revenue with no approved products, reporting net losses of $383.2 million and zero product revenue over the trailing twelve months, underscoring its dependence on external funding (StockAnalysis).

The company’s reliance on equity financings is evidenced by its upsized $650 million public offering in March 2026 and a $747.5 million secondary offering in May 2026, which may dilute existing shareholders (GlobeNewswire).

Diversification risks persist as non-epilepsy programs lag, with Phase 3 MDD topline data not expected until H1 2027 and early-stage pain candidates completing Phase 1 in H2 2026, delaying potential revenue streams beyond epilepsy (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

XENE Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

XENE Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XENE

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Following its Q1 2026 earnings, Xenon reported a cash runway into 2029, ensuring funding for late-stage trials, the planned NDA submission, and commercial preparations (Nasdaq).

Analyst consensus is overwhelmingly positive, with 11 analysts rating XENE as a “Strong Buy” and an average price target of $72.18 implying roughly 33% upside over the next year (StockAnalysis).

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.